ReviewBMC pediatrics2026
CASPR2 antibody-related neurological syndromes in children: three cases report and literature review.
Review in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanding the clinical spectrum of pediatric CASPR2 antibody-associated autoimmune encephalitis: a multicenter case series.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContactin-associated protein-like 2 (CASPR2) antibody-related neurological syndrome is well defined in adults, while data in children is rare. We perform this case series and literature review to ascertain the clinical features of this disorder in children. CASE PRESENTATIONS: We describe three cases who were diagnosed with CASPR2 antibody-related neurological syndrome, and then systematically characterized clinical features, therapeutic responses, and outcomes in 64 patients in literature. Among the 67 patients, the median age was 8.4 years (range 0.5–18), with a male predominance (65.7%). The most characteristic symptoms of CASPR2 antibody-related neurological syndrome include psychiatric abnormalities (68.7%), sleep disorders (55.2%), dysautonomia (44.8%), movement disorders (43.3%), seizures (41.8%), neuropathic pain (34.3%), and cognitive disturbances (31.3%). Autoimmune encephalitis (AE, 62.7%) was most frequent, followed by Morvan syndrome (MoS, 26.9%) and peripheral nerve hyperexcitability (PNH, 7.5%). CASPR2 antibodies are typically detected in serum (85.1%), but rarely in CSF exclusively (3.0%). Investigations revealed abnormalities in CSF analysis (22.9%; 13 AE, 5 MoS), brain MRI (24.1%; 11 AE, 3 MoS), and EEG (67.3%; 26 AE, 7 MoS). Neoplasm was not found in our case series and literature review. Regarding treatment, 46 patients received first-line immunotherapy alone, while 5 required second-line treatment. Immunotherapy demonstrated highly effective, with 95.8% achieving a favorable outcome (mRS score ≤ 2) and a low recurrence rate of 5.1%.
conclusionsWe therefore recommend that all children presenting with new-onset psychiatric abnormalities, sleep disorders, dysautonomia, movement disorders, seizures, neuropathic pain, and cognitive disturbances should be suspected of having CASPR2 antibody-related neurological syndrome. Neoplastic processes are rare in pediatric patients. Early recognition of the disease is important because it responds well to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.